Mutual of America Capital Management LLC Has $4.25 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Mutual of America Capital Management LLC increased its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 12.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 367,866 shares of the company’s stock after acquiring an additional 40,787 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Roivant Sciences were worth $4,245,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Natixis Advisors LLC grew its position in Roivant Sciences by 8.3% during the 3rd quarter. Natixis Advisors LLC now owns 153,717 shares of the company’s stock worth $1,774,000 after purchasing an additional 11,726 shares in the last quarter. Entropy Technologies LP purchased a new position in shares of Roivant Sciences during the third quarter valued at $152,000. Covestor Ltd raised its position in Roivant Sciences by 9.1% during the third quarter. Covestor Ltd now owns 19,190 shares of the company’s stock valued at $222,000 after buying an additional 1,605 shares during the period. Amalgamated Bank lifted its stake in Roivant Sciences by 5.8% in the 3rd quarter. Amalgamated Bank now owns 207,486 shares of the company’s stock worth $2,394,000 after acquiring an additional 11,358 shares in the last quarter. Finally, AlphaCentric Advisors LLC boosted its position in Roivant Sciences by 13.6% during the 3rd quarter. AlphaCentric Advisors LLC now owns 100,000 shares of the company’s stock worth $1,154,000 after acquiring an additional 12,000 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. Finally, Bank of America lifted their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.93.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the transaction, the chief operating officer now owns 617,470 shares in the company, valued at $7,193,525.50. This trade represents a 13.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Matthew Gline sold 1,983,257 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the completion of the sale, the chief executive officer now owns 17,870,543 shares of the company’s stock, valued at $210,693,701.97. The trade was a 9.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,577,309 shares of company stock valued at $42,151,184. Insiders own 7.90% of the company’s stock.

Roivant Sciences Stock Up 3.2 %

NASDAQ ROIV opened at $11.86 on Friday. The company has a 50 day moving average price of $11.69 and a two-hundred day moving average price of $11.32. Roivant Sciences Ltd. has a 12-month low of $8.61 and a 12-month high of $13.06. The stock has a market capitalization of $8.77 billion, a PE ratio of 2.10 and a beta of 1.24.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.